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Drugs are an important factor of production in health care. They constitute a 
significant proportion of health care expenditure in both developed and 
\ 
rendering of drugs an important health care 
concern. Previous studies have 
on drug financing spedfically 
V..., .... "''''i .... on health care financing in 
more so in least developed This 
study therefore to provide an overview of the drug-financing situation in 
Uganda demonstrating the flow of funds for drugs in health sector. study 
further whether financial resources could be 
over time and assesses financial of resou rces for in the 
public sector 
Health Care 
uired to meet drug component National Minimum 
collection methods involved _"""run interviews with key informants in the 
relevant institutions and document of records and other major 
relevant publications. The data obtained was using 
methodologies. Finandng mechanisms were using a framework 
consisting of regarding viability, reliability and of funding. fund 
for health were analyzed the modified National 
Health Accounts methodology finally financial sustainability was as~)es 
using projections from the available financial resources. 
The study findings reveal a mix financing mechanisms from both the public 
and the employed to make drugs available to the population. The 
largest source drug is out-of-pocket households 
followed by government revenue including donor support. There has 
been a noted increase in drug funding in the public sector though this is not 
adequate to cover the quantified drug need in the country. The of the market 
for drugs over the period (2001-2004) with an total 













available financial resources for drugs will not be able to cover predicted drug 
aCI<::aCle more so with the requirement within the National Minimum Health Care 
introduction of drugs to treat new diseases like and the 
change to more expensive ""C'!:>'I'rYU::I for endemic 
The study concludes with recommendations urging government's 
commitment to allocate more resources to health and consequently to drugs so 
there is less on donor funding. It recommends that more effective 
means of utilizing available resources by mobilization of domestic resources 
including out-of-pocket payments through better-designed well-managed 
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CHAPTER 1: BACKGROUND OF THE STUDY 
1.1 Introduction 
Health sector reform has taken place in developing countries over the last twenty 
years aimed at improving the health status of the population. The main challenge 
concerning financing for drugs is to define and utilize those options, which will 
most efficiently ensure a universal access to essential drugs (Pan American 
Health Organization 1998). Drugs are a key component in delivery of health 
services, they are used to save life and improve health; drugs are costly and 
represent a large proportion of health expenditure in most developing countries 
(Dukes & Quick 1997). Drugs are special commodities that affect the utilization of 
health services and have both a political and economic impact. In this study the 
term "drug" refers to pharmaceutical products and medical supplies. 
Drug financing should be envisaged within the whole context of health care 
financing. Health care financing in Uganda has been influenced by a several 
factors like the level of economic development, historic colonial rule and political 
factors. The National Health Accounts carried out for the financial years 
1998/99,1999/2000 and 2000101 showed a low level of funding to the health 
sector from all sources (Ministry of Health 2004a). The policy on health care 
financing is quite articulated to meet the objectives of the National Health Policy 
in broad terms but the funding is not forthcoming to meet the set targets. 
Subsequently, drug financing in Uganda has not been well defined for the whole 
health sector so as to devise policy changes that would improve the existing 
financing situation for drugs. Although information on public drug funding and 
expenditure is available, comprehensive organized information on drug financing 
and expenditure in the whole health sector is lacking. Drug expenditure reviews 
are necessary to understand how best reforms in policy tools and objectives can 













mechanisms should be evaluated using various criteria efficiency 
sustainability of the mechanisms to 
This study evaluates implications sustainability funding sources for drugs. 
In to achieve sustainable financing outlook on 
all funding mechanisms is just 
1 Political Background 
.... "",nr= 1986, the country underwent a wave of political turmoil that left many of 
government systems in disruption including the health 
government that took over power in 1986 ushered in a new 
governance based on consensus building to re-structure the 
the whole country as a whole. The political environment of Uganda is 
stable, with the country's democracy deepening as 
current 
of 
continuing efforts to improve its ways of exercising political, and 
managerial authority (Organization for Economic Co-operation and 
2002). However, a few areas are still ravaged by insecurity and for 
resolution, 
1.3 Social Economic Environment 
The government has pursued economic policies 
programs with major support from development 
by disbursement of resources for Heavily 
Uganda's external debt sustainability 
(Muhebwa, Mugarura & Mugambe 2000). Income 
nCl'fUt".=n the well-off and poor despite government's to 
and monetary policies. Most of the households are engaged in 
(HIPC) thus 
through 
farming. major source of foreign exchange is agricultural exports comprising 













In a bid to 
government 
the top 
with poverty and its on people's health status, 
put in place a multi-sectoral poverty alleviation action plan with 
being universal primary education, primary health rural 
water and sanitation, rural roads maintenance and agricultural extension and 
modernization (Ssengooba & McPake 2001). 
1.4 J\l8.1l'\1I,I'!II\lI1 of the Health Sector in Uganda 
The health in Uganda according to and delivery is categorized 
into not-for-profit and The ministry of health is 
responsible service delivery in the public with the exception of 
ministry and the police force that independent health services. 






policy formulation, supervision, coordination and resource 
policy in 
the central level. Under 
III, II and I. The level of care in 
forms the next of 
are sub-districts and 
health sector is classified as 
follows: primary care that addresses the majority of care needs in form of 
basic and preventive care is health centers III and II. 
Secondary care in form of curative care is in hospitals at regional, district 







professionals and advanced technology is provided at academic 
hospitals. 
nr .. """" of nrl\,''''''TCI pharmacies, private clinics 
and drug shops. professional councils 
to ensure adherence to practice and professional 
private-for-profit is made up of mission hospitals owned by 
international and national non-governmental 
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Major within the health was marked by the development of the ten-
year National Health Policy launched in 1999/2000 (Ministry of Health 2004b). 
Under the bid to utilize result-oriented management and within the 





beginning financial year 
Annual assessments are carried out to 
evaluate in the health and pave way improvement. One of 
the outputs is to deliver a National Minimum Health Care (NMHCP) to 




comprises of interventions considered to improve morbidity and 
in the country. 
Sector Report (2001) showed that the 
funded and was operating at less than half of the minimum 
is grossly under 
to deliver the 
National Minimum Health Care Since drugs are required to treat the 
priority like malaria, they form a critical component in of 
National Minimum Health Some of interventions 
including treatments are unknown in the local 
have turned out to be beyond the of available 
resources (Ssengooba 2002). In particular, the extent to which the drug 
component of the National Minimum Health Care Package under funded is not 
clearly known. 
It the flow of to service delivery for health is 
by inefficiency, a major constraint to maximizing output in the 
health sector. flow of drug funds in the country have not specifically 
mapped out and only estimates of lump sum figures are reported. It is not clear 
how drug funds are disaggregated to various financing agents health care 












1.5 Health Indicators 
"The average healthy life ex[)ec'[a 41 for men and 43 for 
women due to the HIV/AIDS 
dying between the age 15 and 59 
1000 for women" {World Health 
1000 births (World Health Organization 2002) 
and further confirms the need for improved health 
(probability of 
1000 for men and 431. per 
infant mortality rate of 
low health status 
According to 
the burden of disease study in Uganda conducted in 1 75% of life years lost 
to premature death are due to preventable like malaria, acute lower 
respiratory infections, AIDS and diarrhea (Ministry Health 2000). 
1.6 The Ugandan Pharmaceutical Sector 
The Ministry of Health has the broad responsibility over 
the country. Regulation of the pharmaceutical is 
autonomous legislative body, the National Drug Authority that is 
registration of pharmaceutical products and enforcement 
drugs in Uganda. Retail pharmacies, nm,Plt,aI 
provide the major outlets for drugs in 
company may own a pharmacy as long as 
.. "1'.0.,,.01'1 pharmacist authorized by the Pharmacy 
In 2002, government reviewed the National Drug Policy to 
and developments in the health sector pertaining to drugs. 
Drug Policy was implemented as part of the Health Sector 
forms an integral part of the overall national health policy. One of 
elements of the health policy is to develop and implement a 




is under a 
National 
resources for the health sector and utilizing these on "'I"\C~T_CiTTQ,""T priority 















contribute to the attainment a good standard by the population 
ensuring availability, affordability at all 
essential drugs of appropriate quality, and efficacy and by 
promoting their use (Ministry of Health 2002b). In to ensure access to 
drugs, the policy aims at making such drugs affordable available to all parts 
of the country. Another major objective of the National Policy is to 




National Drug Policy. 
the required 
specific strateg ies 
aimed at attaining 
Drug financing mechanisms namely government tax 
and donor funding put in place 
to the of this objective 
the that no research has conducted to 
drugs. In order 
been drawn up to 
overall goal of 
user fees, health 
OVT,onT to which 
not known. This reveals 
how far this policy 
objective has been achieved. Further more the sustainability of some 
in place remains questionable. 
Many care reforms that place over years have had an 
effect - or indirect - on way drugs 'are . In the period between 
1988 and 1994, drugs in the public sector were mainly provided through 
Essential Drugs Program promoted on the basis of the drug concept 
and funded by the Danish International Development Agency (DANIDA). Drug 
procurement for the public sector was based on a push 
were to health units on a quarterly basis in drug kits. 
When program was the government was left with the 
responsibility ensuring the supply good quality drugs with the available 
scarce resources. In 2003, a new pull system based on 














drugs from the national major supply of drugs 
to the public sector is mainly through 
sec;tor cannot The role of the 
pharmaceuticals in lu-;",.-;n J 
for 
to 90% of all 
spending on drugs 
drugs to the private 
clinics and drug 
vIQ,C>\.4UlvL, Madrid & Quick 1 Uganda, provision of 
manufacturing capacity, most of the 
out through private pharmacies, 
a very small pharmaceutical 
are imported from foreign countries. 
The exact size and rate of growth the market is not known. 
Drug financing cannot be viewed independent of health financing, as drugs are 
critical towards improvement of health and delivery of health Financial 
sustainability of drug supplies is important to maintain such services for 
advancement of health and welfare of the population. In this context financing 
mechanisms for drugs, are quite similar to those for financing in Uganda. 
Public general revenue, which is mainly obtained from a 
significant reliable source of funding for health 
expenditure on health in 2002/2003 was 
public 
(Ministry of Health 2003a). 
There are several factors that influence the amount 
and subsequently to drugs. There are competing 
development, industry and defense that may be given 
Within the health sector, drug expenditure is 
health 
nrlr,rltu than health. 
Financing of health services has mainly through this 
applies similarly to drugs. This kind of financing concern over 
sustainability. User fees were to 
compliment government funding for were abolished in the 
public sector except for private wings large 
proportion of the population is believed to purchase 
private sector. Community financing a growing source of 
mobilization of resources for both health and drug led to 
7 
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of community financing 
as a form of health care 
countries. Various financing mechanisms 
to determine the level of funding for 
sources. 
1 Problem Statement 
rural areas. Private 
developed in most 
not been explored 
from the different 
National Drug Policy is explicit in its recognition drug financing among its 
key objectives. However, it is not clear how much drug-
financing mechanisms contribute towards this goal, in proportion and the 
major uses of the drug funds. Further to this the exact pharmaceutical 
in Uganda and its growth has not clearly 
development related to the pharmaceutical sector 
1 
National Minimum Health Care 
for drugs in the public and private not 
sources of funding it is not known whether 
overtime. 
and Justification for research 
to 
From the 
can satisfy this cost 
health care reforms have brought about re-organization and restructuring 
of the health sector including development of the National Policy. No 
evaluation has been undertaken to assess of drug 
financing as a national drug policy goal. There is no approach to 
show how drugs are financed in Uganda, to illustrate 
can 
are sustainable and whether they 
drugs to the population. The study is nec;es~)a 
flow of drug funds in the whole health so 














"1'1~""'''''O on whether the available is in meeting the 
National Minimum Package drug requirements. 
1.9 Objectives of the study 
Aim: 
To evaluate drug mechanisms and expenditure with respect to 
and access medicines in Uganda. 
Objectives: 
1. To map 
country. 
drug mechanisms and patterns in the 
2. To and analyze drug financing and from 
different sources of funding over from 
To assess sustainability of current drug financing relative to the 
National Minimum Health Care Package requirements. 
4. To make recommendations on how to improve the of drug 
financing for 
1.10 Outline of the dissertation 
The dissertation is outlined as follows: 
I n a review of concepts on health care financing is with an 
on previous on drug financing. A framework for analyzing financing 
is principle and significance of using National Health 
Accounts methodology for analyzing drug expenditure is presented different 













In chapter framework for analyzing drug funding mechanisms 
and sources funding is offered. This is followed by the methods to obtain 
and analyze 
Chapter 4 the findings of the study by giving an account of financing 
mechanisms funding flows for drugs in matrices from sources through 
financing to health care providers. Drug expenditure in public as well 
as the private sec;[or is further offered including expenditure of drugs to 
level of care in public Finally financing of the drug within 
the National Minimum Health Package is in 
available resources within n:"""<::>,,u period. 
The key drug financing and expenditure and implications for 
sustainability financial resources are discussed in chapter for 
the observed drug trends are also given. 
Finally, chapter 6 conclusions from the study followed by policy 
recommendations, which point out the different alternatives that can 












CHAPTER 2: REVIEW 
2.1 Introduction 
This literature on theoretical approaches and 
regarding health care financing, drug financing and expenditure. A framework for 
analyzing financing mechanisms is presented. The principle guiding 
the National Health Accounts methodology and its modification is 
use of 
Finally a concepts on financial sustainability is 





a and I"rITII"~ function of the care 
so that access to appropriate health 
. In order to improve financing of health the 
to be employed: reduction of 
payments increase accountability of purchasing and 
providing health improve the pooling of resources and raise funds 
through efficient means by reducing administrative costs (World Health 
Organization 2003). studies have been conducted to examine health 
care financing and in different countries. The information obtained is 
useful for evaluating health systems including international 
Musgrove, Zeramdini & Carrin (2002) compared health-financing patterns for 1 
World Health member for 1997. Their 
total health public on health with a in 
income in 
health 
are more 1"1"\''\l''o.rn&::.1'I 
in 
income of US$8000 
compared to low 
although in low-income countries the total "" ..... ~,.nl'l"n .... on 
World Report (2003) high income 
of spending, cost containment and equity 
resources are relatively plentiful with 
health expenditure ranging from US$1000 to US$4000 
countries with income per capita of less than US$1000. 
11 
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The to provide public gO()OS and services with 
makes public on health in 
important. health financing data is needed to 
failures as 
particularly 
collected in order 
support policy proposals and to help in implementation (Rannan-Eliya & Berman 
1994) so that decisions are based on evidence rather than opinions. 
Subsequently, policy analysis a useful tool for management in the 
health and for developing that help the implementation 
of any care financing (Gilson 1998). an appropriate 
policy is used, strong factors and influence implementation 
of health care financing policies (Gilson et al 2003). opportunity to effect 
policy usually during political transition as experienced by. the 
formulation of the National Drug Policy after the rise of the Aquino government in 
1986 1994). This is quite similar to that in Uganda where a 
point occurred in 
in 1986. 
was the implementation of 
plan the health financing strategy 
health sector when 
one of the 
Health Sector 
government 
in the health 
Plan. Within this 
out methods that will promote increased 
protecting the poor vulnerable groups in efficiency, fairness, risk pooling 
a manner that is sustainable. Although the level of spending changed, 
mechanisms seem not changed are mainly five broad 
revenue include general 
tax donor funding, insurance, payments and 
voluntary and private health The preferred of funding health 
care in many countries all over the world is through public or private 
insurance schemes because of unpredictability illness and the 
accompanying financial required to obtain quality health care (McCarthy 
1994). insurance t"'f'\\,I&:or!:UI&:O means large out-of-pocket expenditure or 














2.3 Drug financing and expenditure review 
The market for drugs differs from standard 
is referred to as market failures. Market 
externalities and information bias. For 
ng::nrITI\i'l:::lJ markets LI'¥,..,C;U.AY'¥ of what 
competition, 
intervention is a 
prerequisite to correct for 
provide all the health 
appropriate financing mechanisms are OC't'<'3t'\1 
the whole population. 
not 
for ensuring that 
ensure access to drugs to 
Drugs constitute a significant proportion of health care 
developed and developing countries rendering financing of d 




drugs responsibility between the government and patient for financing 
although the task to ensure that essential drugs are to all in 
need rests on the government (Department of Health 1994). In Malawi, 
National Drug Policy aims to ensure sufficient funding to provide drugs 
at the lowest possible cost based on proper drug quantification joint 
involvement of different parties including government, Non-
Governmental and individuals in funding of drug supplies (Ministry of 
1991). Drug expenditure in the developed world is on 
example, pharrnaceuticals increased their share of total health care I:::lJVI .... l:::lJrH"I 
in from about 9% in 1990 to about 14% in 1 (Henriksson, 
& Rehnberg 1999). The pharmaceutical sub-sector typically c;n,,"'.V .... 1 
of expenditures in the developing world 
Tomson & Syhakhang 1997). 
greatly among countries with a wide disparity 
countries. "In established 
1.0 .. ·.,.,. . :.'" less than 40% of total 
while more of pharmaceutical costs are paid through public 













quarters of pharmaceutical expenditure are privately financed. Despite this 
situation the share of GOP spent on pharmaceuticals is similar in different 
regions ranging between 0.6% to 0.9%" (Bennett, Quick & Velasquez 1997). The 
per capita expenditure on drugs relates to the level of drug supply in a specified 
country. According to World Health Organization (1997) a less than US$5 per 
capita drug expenditure means that a larger segment of the population have poor 
access to drugs; US$5 - $10 per capita drug expenditure implies that the drug 
needs of the population are adequately covered; more than US$200 per capita 
drug expenditure like that observed in industrialized countries indicates over 
consumption of drugs. Much as the aggregate figures give an indication of level 
of access, it is important also to focus on disaggregated drug expenditures that 
unmask the differences in expenditure of drugs for various diseases or various 
levels of health care (Henriksson, Hjortsberg & Rehnberg 1999). Some of the 
work carried out by World Health Organization has included assessment of public 
financing for drug benefits within social health insurance schemes, a review of 
experiences with user fees for drugs and greater input from the planning of 
development bank loans for pharmaceutical projects (World Health Organization 
2004). The system of user fees in the public sector adopted by many developing 
countries as part of the economic reforms was aimed to protect and support the 
vulnerable groups by exemption incremental fees (Chisadza, Maponga & 
Nazareli 1995). However the system requires high administration costs especially 
for exemptions. The Bamako initiatives were implemented to increase access to 
increased availability of drugs. Studies conducted in Africa and South East Asia 
reveals improved availability of drugs in rural areas but the direct profit incentive 
in the system leads to supplier induced demand through poly-pharmacy, "which 
could be irrational" (Uzochukwu, Onujekwe & Akpala 2002). In some cases 
revolving drug funds have established a stable supply of essential drugs and 
increased utilization of health services despite a drug fee (Murakami et al 2001). 
Experience indicates that national user fees systems have generated an average 
of only around 5 percent of total recurrent health systems expenditures, gross 













complimentary financing mechanism to central government revenue and on 
own is .to close resource gap in the public health sector. Similar 
sources of funding health care have used to fund drugs. Drugs accessed 
though the public are mainly funded by government tax revenue. However 
to ensure adequate and stable financing for drugs other mechanisms to be 
explored. shortage of public funds for drugs has various systems of 
recovery, particularly in Sub-Saharan African including community financing 
and sharing 1994). 
relating to drug financing is usually incomplete, disaggregated and in some 
cases unavailable. of applies to developing countries like 
Uganda. A number of studies focused on analyzing financi g mechanisms 
of drugs for diseases like malaria for example the study by Haak (2003) 
focused on improving affordability and financing of artemesinin- based 
derivatives. Others examined financing of defined health services like 
maternal health services in Uganda (Ssengooba & McPake 2001). More 
specifically, a case study on financing of medicines in Uganda was conducted by 
the Ministry of Health but only focused on the public sector ( of Health 
. 2003c). study found out that drug supply are under-funded by 66% 
and could not conclude on sustainability of the drug financing 
mechanisms. Drug financing like health care financing is influenced by several 
factors not necessary within the health sector. include the political 
environment, macroeconomic policies and international policies at both national 
international level. The decentralization policy offers an illustration of such 
influence. The central government created the decentralization strategy 
in a move to involve in decision-making regarding resource allocation so 
that local priorities are taken into consideration (Ministry Health 2003b). 
question is whether drug funding as a major concern national level within the 
National Health Policy will remain and considered a priority at district level 












Whereas 1 of the recurrent health budget in high commitment countries 
allocated to only 5% of the recurrent budget is for drugs low 
commitment countries (Bennett, Quick & Velasquez 1 stated earlier, 
drug financing one of elements of the National Drug Policy in 
Uganda is explicitly stated within the policy document. According to 
Ratanawijitrasin, Soumerai & (2000) various methods that have 





severely weakening the validity of the and usefulness 
obtain valid and 
to analyze the World 
and Tomson 
admittedly with a 
in the pharmaceutical 
used a 
degree of 
worldwide and acknowledged 
usefulness of research evidence to develop pharmaceutical sector policy. 
study found out that 16% (US$1 billion) of the total World health, nutrition 
and population budget has 
pharmaceutical activities in the 
1995 and of about US$1 
drugs supplies. It is 
committed to 
countries 
or credits supporting 
the period 1989 
been committed to procurement 
how much financial support goes into 
the pharmaceutical sector in Uganda from such international development 
organizations. In addition it is not whether this funding is in form of 
that have to paid back or that indeed country's t'lC.":>I1't'I 
economy. Many studies on drug management have only on the 
pharmaceutical supply system very few on financing of drugs (Dumoulin, 
Kaddar & 1998). Drug is of utmost concern because with the 
scarce resources available and the unequal distribution of resources there 
is a much-felt to ensure efficiency, equity and sustainability. 
2.4 Approaches on Analyzing Drug Financing Mechanisms 
Since drug is viewed within the context of health a similar 
approach to analyze health care financing mechanisms may be employed. 












financing that focuses on revenue generation, pooling of 
purchasing and providers. Financing mechanisms may assessed using 
following criteria: access to drugs; use of drugs, equity, efficiency, sustainability 




of financing mechanisms has based upon the 
level of health impact, equity, and 
& Monasch 1997). This study focused on reliability, 
level of funding and viability of drug financing mechanisms such as~)ec·ts 
have a direct linkage to sustainability of funding sources. 
Use of the National Health Methodology 
Empirical studies demonstrated use of various methodologies to obtain 
17 
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National Health Accounts been used to develop c>~r~.~ot'1 to policy 
design and implementation. In other studies, the methodology has 
to facilitate example the sub-analysis to resource 
flows for HIV/AI 2004). In this way 
Accounts framework to enable data capture of 
related to 
only on who 
and on what 
methodology therefore provides an overview not 




An adapted version of the 'sources and 
DrolDDlsea for developing countries because such 
structures than are found in developed 
2.6 Financial Sustainability 
In order to review financial sustainability, it is useful to examine 
expenditure (Thomas & Muirhead 2000). According to Bossert (1990) a 
comparing the sustainability United States government-funded health 
in Central America and found that these were less firmly sustained in 
Africa. The study and project characteristics that were 
related to Financial sustainability can only 
achieved when resources available are able to meet expenditure 
and support a of If the demand for drugs exc:eeC1S 
available resources, the health system is left with only four options: improve 
efficiency, increase financial reduce demand or accept a decline in 
quality of care (Dukes & Quick 1 Sustainability of the total funding source 
known. In addition, sustainability of 
Iror'no.lnT within the National Minimum Health 
available for drugs in Uganda is not 
the estimated cost of the drug 
Care Package has not 
implementing a 
mechanisms of accountability 
financing 1 
Achieving sustainability 
to develop skills, systems and 
ensure effective implementation of 











sustainability; financial sustainability of programs or of funding sources. This 
study aims to examine financial sustainability of funding for 
financial viability of drug financing mechanisms and the 
It explores 
whether such 
mechanisms are able generate income to cover the costs of drugs. 
Kutzin (1995 P 17) defines financial sustainability as reformed 
system provide a level finance to it to function 
effectively over time without needing a substantial injection external support. 
Others understand financial sustainability as the ability a country to mobilize 
resources whether from domestic or foreign resources to reliably meet 
the required of a service. 
One of assessing financial sustainability is to follow spending on 
which are particularly sensitive to changes in government revenue, and 
how these are financed (Hutton 2000). of the that may 
be to examine financial sustainability include: exploration of the mix in 
funding sources and expenditure of revenue from these funding; 
comparing the of GDP on health on drugs per capita 
utilization for specific such as drugs (Kutzin 1995). 
Summary 
This given a of literature with regard to health care financing 
and how drug financing is linked health care financing. An overview 
on perspectives studies to drug financing has been documented. 
Economic concepts and approaches towards financial sustainability have been 
explored. literature shows that studies on 
care financing and expenditure in general and have been conducted 
mostly in developed countries. the encouragement to impart 
skills and in the areas of drug financing in least developed nations 
progress has been slow. on drug financing in low income 












few in Africa to enable international comparisons. Even at the national level in 
Uganda, there is no information regarding disaggregated funding for drugs within 
the whole health sector. This study aims to cover some of the literature gaps by 
reviewing financing mechanisms and sources of funding for drugs in the both the 
public and private health sector in Uganda. The study further aims to provide an 
insight into the financial sustainability of the funding sources and that for the 











CHAPTER 3: RESEARCH METHODOLOGY 
3.1 Introduction 
This chapter presents the methodology used in the study. A conceptual 
framework that clarifies the approach used for data analysis is first presented. 
The study design employed and the methods used for data collection and 
analyses from the different sources are then described. Limitations of the study 
methodology are finally given. 
3.2 Conceptual Framework 
The National Health Accounts framework developed by Berman (1996) provides 
an analytical approach for health expenditure requiring the calculation and 
presentation of national estimates through a "sources and uses" matrix; allowing 
for extensive disaggregating of sources of spending beyond the general 
categories of "public" and "private" as described by the Organization for 
Economic Cooperation and Development methodology. It provides a systematic 
structure for defining uses according to several important and mutually exclusive 
classifications. 
In this study the framework is modified and applied to show the flow of drug 
funds from immediate "sources" through "financing agents" to "providers of health 
care" as illustrated in Figure 1. "Sources" refer to where the funding is coming 
from. In the framework, financing sources are the sources of drug funds that 
mainly include public sources, private not-for-profit and private for profit sources. 
The drug funds then flow through various financing "agents" that refer to those 
institutions or intermediaries, which receive the money and use it to either payor 
purchase drugs. These are broadly classified into the Ministry of Health including 
vertical programs, non- governmental organizations, private health insurance 
firms and households. The drug funds are finally channelled to the "uses" which 











care provider are classified into three major groups; public 
health centres; private not-for-profit that 
for hospitals, clinics and private for profit providers that sell drugs 
in hospital pharmacies, clinics and drug shops. study further 
the total drug funding available in the public 
was to meet the drug requirement in the National Minimum 
Incorporating assessment of drug financing in of sustainability 
modified National Health Accounts framework. Sustainability is defined in two 
a of a health system, sustainability of 
system continue its normal activities in the future, should foreign 
withdrawn (Knowles, Leighton & Stinson 1997) and stability of 
definition is concerned with the sufficiency and 
n<:tl"tl"'':.~ into health sector (Thomas & Muirhead 
viewed from two financial' and institutional. 
health system performance 
Leighton & Stinson 1997). This study 
of the funding mechanisms available for d 
of sources 
in Uganda. 
sustainability of the current drug funding in the public in 
Health 
from 
the estimated cost of drug requirements in the National Minimum 
is reviewed. The total public drug funding funding 
government tax revenue and donor support. 
rrH,,,,," .. :,,r are 
University of Cape Town






















Private Not for Private For Profit 
Profit Sources Sources 
- Non- - Employers! 
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3.3 Study design 
is a descriptive and analytical study of drug financing mechanisms in 
Uganda. national expenditure on drugs as a single line item of health 
for both the public and private sector was Further to 
this sustainability of drug funding mechanisms and that of total public 
financial resources required to meet the National Minimum 
drug requirement was also determined. 
3.4 Study 
I,.."",nrl"" and data collection was LlC':''''',", in two 
Kampala, the capital city where most 
"'TT ...... "'.... for country are found and in Entebbe, a municipal town 
ministerial institutions are based. 
3.5 Method of sampling 
other 
In the study purposive sampling was used for selection of from 




for location of key informants in the health 
Primary on drug financing and expenditure patterns including opinions, 
views and drug financing policy was collected using interviews with 
informants in the from November 2004 to February 2005. Secondary 
was obtained by means of document reviews on drug financing and expenditure 










in Uganda. The trend in financing and expenditure on drugs was determined for a 
three-year period starting from the financial year 2001/2002. The key variables 
that were explored included sources of drug financing and expenditure reviews in 
the health sector. In addition, financial sustainability of available financial 
resources for drugs in the public sector was assessed in relation to the National 
Minimum Health Care Package drug requirement. Data collection methods 
involved collection of quantitative and qualitative data. Financial quantitative data 
on drug financing and expenditure in the public and private sector for three years 
starting from the year 2001 was collected using data capture sheets (see 
Appendix 1). Qualitative data was obtained using face to face in depth interviews. 
Document reviews 
Several documents were reviewed including financial records, annual reports and 
relevant publications. The documents included the National Health Policy 
(Ministry of Health 1999), the Health Sector Strategic Plan (Ministry of Health 
2000), the Health Financing Strategy (Ministry of Health 2002d), Annual Health 
Sector Performance Reports for the years 2001/02 to 2003/04 (Ministry of Health 
2002a, 2003a, 2004a), the National Drug Policy (Ministry of Health 2002b), the 
National Pharmaceutical Sector Strategic Plan (Ministry of Health 2002c), the 
Annual Budget Performance Reports (Ministry of Finance and Economic 
Planning 2002, 2003, 2004a). 
Household survey data from the National Bureau of Statistics was used to obtain 
information on the amount of money spent on drugs by households. Only data for 
one year (2003) could be obtained since the household surveys are carried out 
every three years. Given the short duration for data collection disenabling 
carrying out a national survey and the difficulty in obtaining expenditure in the 
private sector a method of estimation was used. According to Griffiths and Mills 
(1983) trade and production statistics for commodities such as drugs and 
appliances can be used to estimate the cost. Data on drug imports was obtained 













drugs on the market in Uganda. on drug imports was used to estimate drug 
expenditure in the private 
drugs imported by National 
sector and data for 
three financial years. Data for cost of 
which supplies mainly the public 
imported by Joint Medical Stores that supplies the 
Private Not-Far-Profit sec:tor was from cost data for all drug 
data for drugs imported by the private imports leaving a ure 
sector. A 
the cost value of 
wholesale drug 
In - depth semi -
up) up was then added 
give an estimate of the 
Face-to face in depth InT,:.n/lIO\A/C! were held with key informants in the different 
government and private Appendix 3 and 4). Participants 
comprised of leading key who were interviewed using purposeful 
sampling and snowballing were presented according to 
public and private sector. 
In the public sector, were carried out to obtain data on drug financing 
mechanisms and sources funding for drugs. to face in- depth Interviews 
were conducted with ing personnel from key departments in the Ministry of 







Project). Interviews were 
International supporting 
Planning (department responsible for 
control for the health sector) and National 
with key officials from the 
Danish International Development 
International Children's Emergency 
International Development 
conducted with the relevant key 
like World Health Organization (WHO), It was 
possible to obtain from Department for International 










framework and thus channel their financial support through 
Finance and Economic Planning. 
Ministry 
In order to obtain data for _.-I\,,,,n,,, Not-For-Profit sector, an interview was held 
with the General Manager of Joint Medical Stores because most 
for the mission sector are 
supplies drugs to all health 
from 
to 
institution. Joint Medical 
Catholic Medical and 
the Protestant Medical Medical Bureau mainly depends on 
drug supplies from Joint Medical Stores. Therefore data 
this source was omitted avoid double counting. 
the private sector, a total five health insurance companies were 
visited. These included: 
• African Air Rescue (AAR) 
• Micro care (formerly known as AON) 
• International Air Ambulance (IAA) 
• Case Medicare 
• American International Group 
It was assumed that other private health 
companies or Health pay medical 
ovrlon,C!oC! for their employees at specified clinics. Including will 
mean counting because these are included in the private that 
hospitals, medical and drug 
in depth interviews were held with key informants in these 
firms using interview guide (see Appendix 4). The amount of spent on 
and drugs from 2001 to 2004 was extracted from 
















3.7 Data Analysis 
Basing on the principle and modification of National Health Accounts 
methodology (Berman 1996), study out to obtain data on drug financing 
and expenditure at a national level. 
different drug financing mechanisms in 
presented as they function within the 
country were identified and 
The drug financing 
mechanisms were 
Secondly, the flow 
obtained following modification of 
developed by Berman (1996). 
funds in the country. Using the modified 
funds from the original source to financing 
Another matrix of drug fund flow from 
was then constructed. Drug o=>vr,o=>n,rlltl 
were then compared and 
of funding, reliability and viability. 
sources to healthcare providers was 
Accounts method 
to flow of 





sustainability was carried out using on the growth rate of drug 
financing resources within the review period (2001-2004), growth trend was 
determined by plotting the total drug in billion Uganda shillings for 
the three financial years within the 
the review period was then obtained 
\1.0"'=01"1.0 growth rate within 
to project the total drug 
expenditure in the proceeding The projected figures were compared with 
the predicted cost of the drug component within the National Minimum Health 
Care Package. Qualitative 
based on the trend of support 
allocation to health and 
expenditure as a 
funding for 
sustainability was carried out 
donors as opposed to government budget 
to drugs; comparison of health and drug 












The data was for errors and It was 
analyzed using 2000. 
Qualitative was analyzed using narrative analysis. qualitative 
obtained from was encoded manually on a document manually. 
data was according to the different themes regardingdrug financing 
and sustainability. This was done manually and using the in MS Word. 
The different 
four subsections 
were then presented in the chapter on 
with the quantitative data. 
3.8 data and bias 
is oaf;ea on of drug not 
is a selection bias in 
were interviews nevertheless, it is 







Data on drug expenditures excludes expenditure on traditional medicines, which 
is difficult to Data on drug funds disbursed from Ministry of Finance 
and Planning to other ministries were excluded. for drugs spent 
by firms to workplace clinics were omitted due to the 
in 
It was 
the majority of these firms now 
n~~::OITn maintenance organizations. 
disaggregate data on funding 
Uganda and donor support. It was not 
the National Minimum Health Care Package 
requirements in the public health sector. 
such firms are few 
to private health 
from government of 
spent on 












Being a descriptive analytical research, the study posed minimum risk to 
participants. Before conducting the research, approval conduct the study was 
sought from Research Committee at the University of Capetown, 
South Africa. Authority to conduct study review records in 
Uganda was obtained from the Ministry of Health, Kampala (see Appendix 5). 
Permission to review documents and extract data from all participating 
institutions was obtained from the of the organizations concerned. Face to 
face in- depth interviews were conducted with key informants seeking 
consent thus ensuring autonomy of the persons involved in the study. Before 
interviews, participants were informed about the purpose of the study and were 
requested to participate on a voluntary basis without any coercion. A letter of 
consent was read signed by the participant as proof of consent to participate 
in study appendix As a means to harm, participants were 
assured of choice to withdraw from the interview at any in time. Since 
retrieval of information involved handling financial and other sensitive issues, 
participants were of confidentiality. 
3.10 Summary 
This chapter outlined the research methodology to conduct the study. 
data was based on qualitative and quantitative primary secondary 
from different sources in both the public and health in Uganda. The 
conceptual framework used is based on the National Health Accounts 
methodology, which was modified by incorporating aspect sustainabilityof 
financing resources for drugs. Data was analyzed using Microsoft Excel 2000 












CHAPTER 4: RESULTS OF THE STUDY 
4.1 Introduction 
This chapter describes the main findings of the study. The different drug 
financing mechanisms and patterns are mapped out followed by analysis of drug 
financing and expenditure from different sources funding. Finally the 
sustainability of current drug financing resources relative to National 
Minimum Health Care Package drug requirement is Primary is 
based on interviews with key informants in the relevant organizations, firms and 
institutions. Secondary data was obtained from of documents relating to 
data reported or published within a period of years starting from 2001. Both 
sources data provided quantitative and qualitative data. 
4.2 Drug financing mechanisms in Uganda 
This section presents the different drug financing mechanisms in Uganda. The 
mechanisms are categorized into two groups, public and private. description of 
each drug financing mechanism as it functions in the country is given. Finally, a 
brief report on Social Health Insurance as an emerging financing mechanism for 
drugs also presented. 
It was ex[)reSSE~d by all key informants in the Ministry of health that drug financing 
forms part of National Health Policy (Ministry of Health 1999), is explicitly 
defined in Health Sector Strategic Plan (Ministry of Health 2000) and the 
Uganda Health Financing Strategy (Ministry of Health 2002d). The main goal of 
drug financing as a major policy area within the National Drug Policy is ensure 
that sufficient funds are available to maintain a regular and adequate supply 
the required drugs and equitable access to by population 
(Ministry of Health 2002b). Several drug-financing mechanisms have developed 
over time within the Ugandan health sector and have been established to 
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the above-mentioned goal. The responsibility for implementation, monitoring and 
evaluation of drug financing policy lies mainly with the pharmaceutical and 
planning department of the Ministry Health. The Principal pharmacist said that 
there has been a gradual realization of the of drug financing policy 
in the advent new like HIV/AIDS and new treatments malaria. All 
key informants acknowledged 
development issue. 
importance availability drugs as a major 
In Uganda, drug-financing mechanisms may categorized into either public or 
private, similar to health care financing mechanisms. The different sources of 
funding disburse funds through various funding mechanisms as shown in 
Table 1. All key informants in the govemment cited government tax-revenue 
including donor budget support global initiatives as sources of funding. It 
was further noted that households are a major source of drug funding except it 
was difficult to obtain accurate results due to poor documentation. 
Table 1: Sources of drug funding and their financing mechanisms 
I Financing Source Financing Mechanisms 
. Government of Uganda Central tax revenue 
Donor Budget support 
Donors Donor Project funding 
Employers fees 
Private Health Insurance 













4.2.1 Public drug financing mechanisms 
4.2.1 examines drug-financing mechanisms within the public 
Public drug financing mechanisms comprise of mainly central government 
revenue, donor funding and donor project funding. Funding from donors is 
under public the funds are mainly utilized within the public 
care system. on primary data from informants in the Ministry of 
Ministry of Economic Donor 
supporting International organizations like World Organization 'VV\,H./10i; .... 
with documentary reviews, following qualitative data findings were obtained 
and are presented below: 
a) Central Government Revenue including Donor funding 
government drugs is mainly from revenue cOllecrea 
from taxes. Financing drugs from this mechanism is determined by a 
combination of economic factors, national budget decisions and 
decisions by health ministries (Dukes & Quick, 1997). As such the Ugandan 
government embarked on a new mode of financing government services through 
~p.(-:ror Wide Approach in the year 2001 (Ministry of Health, 2002a). Through 
all revenue and that from donors 
is pooled together through the Ministry of and Economic Planning 
then later distributed to Ministry of Health and other government sectors 
(Ministry of Health, 2002d). 
It therefore difficult disaggregate funds allocated to the health sector for 
from the 
contribute funds 
the health sector 
and 
of 
nOI"'ifil"<3lhl for drugs. 
from donor funding. donors 
some which may earmarked 
Allocation of drug funds is based on a number of constitutional arrangements as 
stated by the Senior Economist in the Ministry of Finance Economic 













that for According to with key personnel in the Ministry of 
Health, Pharmaceutical Division, funds for drugs from the central 





(PAF) that is 
and district health facilities through two main streams: 
transfers 
are delegated funds ariSing from the Poverty Action 
as a Primary Health Conditional Grant 
to 




r\n.:~r~:u health services as <:lnlroo.1'1 upon by countries 
Ministry of 
is direct to the districts on a monthly basis although in reality 
the monthly frequency may not be attained as stipulated. Specific guidelines are 
set out on the utilization of Primary Health Care Conditional Grant. 
guidelines require that 50% and 40% of the funds spent on drugs for 
health hospitals respectively. guidelines further that 
purchases of made at the National Stores. In the 
drugs required are not available, a certificate of non-availability is so 
the health facility the drug supplies from Joint Medical Stores. If the drugs 
are also not in at facility, drug can then be made from 
private sector. Allocation of drug funds among districts is based on a formula that 














from a push to a pull system of supplying drugs 'from 
Drug Accounts were established at the 
Ministry of Health for public Private Not-For-Profit health facilities (Ministry 
Health 2003b). Funds from the national shared services programme 
and the Health Sector Support II Project (funded by the Danish 
government) are disbursed from 
Under this arrangement the health 
line from which orders are placed 
central government to the Ministry of Health. 
at District level are notified of their 
Medical Stores on a monthly 
specified on a list of 
the credit line funds, 50% of the 
districts and the other 50% is distributed 
Medical Stores or Joint 
are only used to purchase drugs 
(Interview data). For 
equally among the 56 
the allocation formula that takes 
factors such as population (I ..... \11, .... ,,\1 data). 
b) Donor Project Funding 
During the review period (2001 - 2004), most of development partners had 
switched from project funding to budget support, thus their funding 
through the government of Uganda (Ministry 
continued to provide financial support directly 
sec:tor through bilateral and multilateral 
area include project funding from USAID, 
a new financing mechanism at 


















Global Initiatives is a way for development partners to fund projects in developing 
countries. The first of these global initiatives to be introduced into Uganda in mid 
2002 was the Global Alliance for Vaccines and Immunization (GAVI) (Interview 
data). GAVI mainly focuses on improving child welfare by reducing child mortality 
rates through provision of high quality vaccines for the six major killer childhood 
diseases that can be prevented through immunization. The next to emerge in 
2003 was the Global Fund for AIDS, Tuberculosis and Malaria (GFATM). 
The Global Fund, an international 'financing mechanism for additional resources 
to the health sector provides funds according to locally developed proposals 
aimed at prevention and management of AIDS, Tuberculosis and Malaria 
(Ministry of Health 2003a). Since drugs form a major input in the management of 
these three diseases, a substantial amount of funds has been utilized to 
purchase anti-retrovirals, anti-malarials and anti - tuberculous drugs. Global 
initiatives have focused on financing priority areas within the health sector to 
provide impact on improving the health status of the population thus promising to 
be a key source of funding for drugs at least in the medium term. 
On health sector program priorities that could impact on drug funding, all key 
informants noted human resource as a major competing input followed by' 
infrastructure, equipment and operational items such as fuel, maintenance costs 
especially at district level. 
4.2.2. Private drug financing mechanisms 
Section 4.2.2 shows the major private drug financing mechanisms. In most 
developing countries, the private sector forms a significant source of funding for 












Three financing mechanisms for drugs in the private sector were identified and 
these include: 
a) Private Not-Far-Profit (PNFP), 
b) Direct private purchases, 
c) Private health insurance, 
d) Community health insurance 
An account of each mechanism is given as follows: 
a) Private Not-For Profit 
This mechanism encompasses funding from local and international non-
governmental organizations. Financing of health services including purchase of 
drugs takes the form of grants or subsidies. The agencies involved in this sector 
are mainly faith-based and operate in collaboration with the Ministry of Health. 
Most of the drugs supplied to Non-Governmental Organizations' facilities are 
distributed through Joint Medical Stores, a Private Not-Far-Profit organization 
that supplies medicines, medical equipment and related health care services to 
Uganda Catholic Medical Bureau (UCMB) and Uganda Protestant Medical 
Bureau (UPIVIB) health units (Joint Medical Stores 2004). 
b) Direct Private purchases 
The most common form of payment for health services in the private sector in 
Uganda is out-of-pocket fee for service. Thus households spend a substantial 
amount of their income on purchase of drugs from government, private not-for-
profit and private for profit health facilities. In government and PNFP health units, 
payment takes the form of user-fees whereas in private for profit health facilities, 
payment is direct out-of-pocket. 
37 
 










a prescribed amount of money to 
delivery, were abolished in government 
(Ministry of Health 2002d) leaving such 
hospitals and the "private window" of 
on financing health services resulted into 
an demand for drugs in public health 
Private Health Insurance 
by 
were companies providing private health 
prepayment for health services that participated in 
insurance does not have large coverage in Uganda. 




change in policy 
health facilities 
(Ministry of Health 
or voluntary 
study. Private 
five firms visited 
of the companies were underwriting other different kinds of 
travel insurance while others were with 
Subscription to private health is of 
in formal employment whereby employers premiums to 
.... ,.",'''''TO health companies who may either provide 
i't1!"'::>I''I'IIH or out oth r health service providers. Premium annum 
VV'oiI''''V to US$800 per annum depending on whether one 
membership (Interview data). All the five health insurance 
provided essential drugs within their health .... <;;>n'<;;>TlT Da(~Kaae. 
the firms, high valued drugs like antiretrovirals were 
and were paid for separately. Drugs were provided 
facilities or public health facilities. From the interview 















d) Community .... a .. n::u health insurance 
Community based health insurance had embarked upon through. the 
Revolving drug fund (Bamako Initiative) but during review period 
schemes had been down and in cases abandoned. The few that 
were operating were in very few districts and had minimal contribution. 
4.2.3 Social Health Insurance 
Social Insurance (SHI) is a financing mechanism that is not in place in 
Uganda. A feasibility study carried out by Ministry Health in 
collaboration with the School of Public Health (Berman 
study recommends a gradual introduction of Social Health Insurance in 
the formal sector. Plans are underway to have a legislative framework within 
which to implement this mechanism within the formal sector in a phased manner. 
4.2.4 Summary 
This section has revealed the different drug-financing mechanisms outlining how 
they function within health care system in Uganda. The country has taken a 
pluralistic approach in which different drug financing mechanisms serve different 
groups population. The show that some of the mechanisms direct 
private and government revenue including donor support are more 
dominant than others in meeting the burden of drug financing in the country. This 
is further illustrated in the section that financing and 












4.3 of drug funding and flow 
t:!O""1' ...... 'n presents the sources of drug funding and expenditure for three 
starting from 2001/2002. flow of funds from sources to 
financing then financing agents to health care providers is examined. 
within 
Sources of drug funding 
1'1 ... 1'"\0.1""1 earlier in section 4.2, are major sources of drug funding 
health sector contribute to the total funding pool for 
2 shows the largest source to be households. It 
lowest source 
in donor project funding in financial year 2003/04 was 
mainly attributed to the funds obtained from the Global Fund Program amounting 
to 20.7billion Uganda shillings (Ministry Health 2004c). Non-Governmental 
Organizations serve as a substantial source of funding for drugs (Joint Medical 
Report 2004). Figure 2 further illustrates an increasing expenditure on 
drugs from all the different sources though different rates with donor 
funding at the highest of per annum from the financial 

















Amount in 80 
billion Ug. 
shillings 60 
Ministry of Health (2004c); Joint Medical 
interview (2004); National Drug Authority imports dat'3ba~;e (2004) 
terms) 
Insurance 
Combining all the financial resources from the sources mentioned above gives 
an the total resource base available for financing drugs within the 
(2001 - 2004). The total drug financial resource increased 
from 1 billion shillings (2001/02) to 210 billion Uganda shillings 
(2003/04) excluding funds from the Global Fund, an increase of 23 
annum over the three-year total per capita drug 
spending from all sources is given in Figure was a steady increase in 
total drug expenditure from all sources over review period though 


































Source: Ministry Health (2004c); The average for 2001/02 is 1 US$ ::: 
Ug.shs.1 2002103: 1 US$ ::: Ug.shs.1881.1; 2003/04: 1 ::: Ug.shs.1936.2 
(Ministry of Finance, Planning and Economic Development 2004b) 
4.3.2 flows for drugs n Uganda's health ct~l"·tnl' 
a) sources to financing agents 
Drug by source in the for three financial 
2001/02 to 2003/04 is presented in Among the five major e1" .. "~",, .... ,e 
financing Households have the flow of drug funds 
(2001/02); 66.4% (2002/03); 57% (2003/04)1 followed by the Ministry of 
This is reflected through out the under review. 
Although the amount of funds flowing through the Ministry of Health from 
Ministry Finance and Economic Planning increased over the review period 
of the total amount of funds for the various years decreased slightly; 
=
=













21 % (2002/3); 20% (2003/4). A slight decline was 
funds spent by PNFP organizations though showing almost half the 
(2001/02); 8.9% (2002/03); 8.3% (2003/04)] spent by the 
. Funds for drugs flowing 'from Donor funding to vertical 
.-:t".I.·",~u drastically up to 13.7% of the total drug funding in the 
2003104. However, funds spent by Private Health Insurance firms 
constant [0.8% (2001/02); 0.9% ; 1% (2003/04)] over 
the period under review. 
 
University of Cape Town
Table sources drug to agents FY 2001/2 2003/4 real terms) 
Source: 
Ministry of Finance Donor PiUJCI,..L Funding iEml)loyer NGOs Household irotal 




Ministry of Health 27. 35.29 ~7 
~~ 
Vertical 1-11 U\,:II <:1111;:> 1.51 4.79 32.48 
-
Private 12.2 14.90 19.7 
~~~ ~~~ 
'1-101 .. "' ..... 83.1 112 135 
Private Health 
r~ 
Insurance 0.96 1.54 2.28 
irotal ~7.20 35.29 ~7.50 1.51 f4.79 32.48 0.96 1.54 2.28 12.2 14.90 19.7 83.1 112 135 124.97 168.22 237.34 
f---~~ ~~ 










b) Financing agents to providers of health care 
The flow of funds for drugs to the various health care providers is presented in 
Table 3 for the three financial years starting from 2001/02. The Ministry of Health 
distributes the drug funds to various levels of care, national, regional referral, 
district and at health center level. Table 3 shows that the Ministry of Health 
witnessed a sharp increase in the year 2003/04 in the amount of funds used to 
purchase drugs at the central level. Funding for drugs at the national referral 
hospitals remained constant (approximately 4 billion Uganda shillings) over the 
review period (2001 - 2004). Regional referral hospitals witnessed an average of 
20% increase in drug funding whereas that for district hospitals was 26% within 
the period under review. 
Private facilities still maintain the highest percentage of the total amount of drug 
funds in the health sector (67.3%, 68.6% and 58% for the financial years 
2001/02; 2002/03 and 2003/04 respectively). These are followed by the non-
governmental organizational facilities and the lowest are the regional referral and 
district hospitals. The total amount of drug funds utilized by health care providers 
increased over the three years by 112%. 
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4.3.3 Public expenditure on 
Section 4.3.3 presents expenditure on drugs in 
that GOP at 9.7% per annum over the 
and increased 
public sector. 4 shows 
period (2001-2004) while 
a rate of 4.8% and 24.8% 
respectively. in GOP was with on 
health and subsequently an spending on drugs. Drug expenditure as a 
percentage of GOP increased from 0.27% in 2001/02 to 0.36% in 2003/04. Drug 
expenditure as a percentage of public health expenditure including donor support 
showed an from to 1 (2003/04). 
Table 4: Expenditure on drugs in the public C>1!'I. ... ''I' .... r (in billion Ug.shs. real 
2001 2002/03 2003/04 
GOP 13215.00 
Government expenditure on health 
207.99 
Government expenditure on health 
includin 361.00 
Public drug expenditure 
%GDP on drugs 
0.27 0.36 
8.9 9.6 
8.6 12.5 13.2 
Source: Ministry of Health Annual Performance Reports 2003a, 2004a); 
Ministry of 
2002,2003, 











Expenditure on drugs compared to other Inputs in the Public Sector 
Various inputs are required to implement health system objectives. Public health 
funds are thus used to provide such inputs. Allocation of health sector budget for 
the FY 2003/04 is hereby shown in Figure 4. Though the 18% allocation on drugs 
appears to be the lowest compared to other key expenditure categories it 
nevertheless indicates a significant proportion of the total health expenditure. 
Figure 4: Allocation of health sector budget by input 
Drugs 
~;~a ~% 
















Drug by level of care 
Table 5 shows a decreasing expenditure on drugs from the central level over the 
review period increasing drug expenditure on vertical programs. In 2001/02, 
district health received drug funds central 
level and this was reduced in 2002/03 by and in 2003/04 by 1 relative to 
the average 18% public drug expenditure was used in 
national, and district hospitals within the review period (2001 -2004). 
Table 5: Public drug expenditure by level care (in billion Ug.shs. real 
terms) 
2001/02 2002/03 2003/04 
Share of total % share of Share of % share of Share of 
drug total total drug total drug Itotal drug 
Levels of care expenditure expenditure expenditure expenditure expenditure 
Ministry of Health General 
10.53 36.7% 12.00 32.5% 23.74 
Hospitals 
5.96 20.8% 8.10 22.0% 8.92 
District Health Centers 
7.45 25.9% 7.25 19.7% 9.54 
NGO Facilites 3.27 11.4%1 4.73 12.8% 5.32 
1.51 5.3% 4.79 13.0% 32.48 
Total public drug expenditure 28.72 100.0% 36.87 100.0% 80.00 
Source: Ministry of Health (2004c); Ministry of Finance and Economic Planning 


















4.3.4 Expenditure on drugs in the private sector 
Household expenditure on drugs 
Household expenditure on drugs is based on the data collected from household 
surveys for the year 2003. Figure 5 shows the highest component of the total 
health expenditure to be drugs (48%), which translates into US$1.9 per month 
per household (Uganda Bureau of Statistics 2003b). 











Source: Uganda National Bureau of Statistics (2003) 
Health Insurance 
Currently, approximately 0.1 % of the population is covered by private health 
insurance and managed care (Interview data). This is a very small proportion of 
the total population that requires access to health care. Most of the insurance 
schemes cover essential drugs to a specified maximum above, which the 
member has to payout of pocket. Some of the firms exclude high-valued drugs. 











companies or Health Maintenance Organizations were visited. Table 6 shows 
that on average over 50% of the membership contributions are spent on drugs. 
Table 6: Use of Membership contribution in Private Health Insurance 
(Figures in billion Ug. shs. real terms) 
Expenditure on health Expenditure on % of total health 
services drugs services spent on 
drugs 
Year 
2001/2 1.7 0.96 56.5 
2002/3 3.29 1.54 46.8 
2003/4 3.9 2.28 58.5 
Source: Private Health Insurance interview data (2004) 
4.3.5 Comparison of public and private drug expenditure 
Figure 6 shows that the private drug expenditure is much higher than the drug 
expenditure in the public sector. This scenario further illustrates the fact that 
provision of drugs in the pharmaceutical sector in Uganda is largely through the 
private sector. In both the public and private sector there was an increase in drug 











Figure 6: Comparison of drug expenditure in the public and private sector 
(in billion Ug.shs.real terms) 
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E 20 « 
0 
I I-I -I , 
2001/02 2002/03 2003/04 
Years 
Ministry of Health (2002a, 2003a, 2004a, 2004c); Ministry of Finance and 
Economic Planning (2004a); Joint Medical Stores (2004); National Drug Authority drug 
Importation (2004); Insurance Interview (2004) 
Summary 
This the sources drug funding in both public and 
private sector. It presented flow of drug funds from the various sources 
through financing to the different levels health care. The findings 
showed households to be the largest source of funding for drugs, which funding 
is eventually spent in the private sector. Drug expenditure in public sector' 
was compared and found to be lower than that in the private sector. next 
section, 4.4 will the findings on sustainability of resources available to 

















4.4 Sustainability of drug funding relative to the NMHCP drug requirement 
This section presents an assessment of sustainability of available financial 
resources for drug financing and compares these resources with the drug 
requirement specified within the National Minimum Health Care Package. 
4.4.1 Costing and Financing of the NMHCP drug requirement 
The National Minimum Health Care Package has been developed with the aim of 
efficiently meeting the basic health requirements of the population in the 
govemment and Private Not-For-Profit health facilities (Ministry of Health 2003a). 
The Ministry of Health carried out costing for drugs as a vital component of 
recurrent costs required for effective delivery of the minimum health care 
package at all levels of health care (Ministry of Health 2000). According to the 
Health Sector Strategic Plan (2000), "estimates of drug consumption were based 
on the national drug quantification exercise c rried out by the National Drug 
Authority. Estimates were corrected for accessibility of the population to health 
facilities (estimated at 46%). An annual per capita drug consumption rate was 
calculated and based on the country population gave the national annual drug 
requirement. Drug costs were estimated basing on the output statistics and 
performance indicators from the inventory of health services in Uganda for the 
year 1996. The vaccine requirement was obtained from the Uganda National 
Expanded Program on Immunization (UNEPI) estimation". The cost of drugs in 
the National Minimum Health Care Package was predicted by the Ministry of 
Health to increase over a period of 10 years starting from the financial year 
2001/02. The costs exclude Anti - Retroviral drugs and pentavalent vaccines that 
are likely to escalate the cost because of the associated hjgh value. 
The resources for drugs in the public sector that were used in the review period 












requirements were not able to meet the target set out in the Health Financing 
Strategy as demonstrated in Fjgure 7. 
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I-+- Budget -c-Actual I 
Source: Ministry of Health (2002d); The average exchange rate for 2001/02 is 1 US$ = 
Ug.shs.1754.6; 2002/03: 1 US$ = Ug.shs.1881.1; 2003/04: 1 US$ = Ug.shs.1936.2 
(Ministry of Finance, Planning and Economic Development 2004b) 
This reflects a large financing gap between the target set out in the NMHCP and 
the actual expenditure on drug requirements within the NMHCP. On examining 
the future trend of funding the drug requirement for the NIVIHCP, a projection was 
made to determine the funding that would be available in the next ten years in 
relation to the resources available in the review period. The projection is based 
on the growth rate of drug 'financing over the review period (2001 - 2004). Figure 
8 shows the trend analysis, which still demonstrates a growing financial gap 
between the projected funds and the cost of the drug component within the 
NMHCP predicted by the Ministry of Health. 
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-D- Predicted drug requirement in the NMHCP 
-+- Projected drug financing resources 
Source: Ministry of Health (2003a); Ministry of Health (2002d) 
4.4.2 Sustainability of drug financing resources 
In order to assess sustainability of drug financing 
were explored to determine the proportion of 
was a growing commitment from 
more of its resources to the health sector. Table 7 
public expenditure as a percentage of GDP 






rl"o,nl'<: ..... o of government's health sector financed by tax revenue is apparent 
from 2001/02 to 2002/03 but later dropped to 57.61% in 2003/04. 
government's health spending financed by donors initially to 38.29% 
CreaSE!O slightly the following financial year, reflecting erratic support from 
donors. Government's drug spending directed towards primary care oec::re.aSE!O 
over the review period. 
in Table 4, section 4.3.3 give an idea about the of of 













of 9.7% per annum while government's """r""",.,.,.. 
of 7% per annum. Public drug expenditure on 
of 50% per annum. 
Table 7: Indicators of Sustainability 
Public drug Public health % of public % of public 
expenditure as health health 
as a % of total expenditure 
GDP financed by 
tax revenue donors 
2001/02 0.26 8.60 54.39 
0.33 9.00 61.71 
0.52 9.60 57.61 
on health increased a 
hand a 








Ministry of Health, Annual Performance Reports \"-V'v"-CI 2003a, 2004a) 
Comparing domestic and 
.:llv1t.:llrln~1 sources of funding 
nrn.:llc>TII" resources C'nr""/C' 
su~)Port drug needs in 
is reliance on 
public and private not-
for-profit sectors. comparison of public versus private sources of 
funding shows that the major source of funding is from private sector in form 
of out-of pocket payments as shown in section 4.3. Out of pocket payments are a 
form of financing d and would not favor and the poor. 
Sustainability also considers utilization issues including 
which are outside the 
informants oWleCloe!o government's in 
funding for drugs. The Senior at the Ministry of 
of drugs per patient, 
sustain ability of 
and Economic 
Planning cited health insurance as a strategy to facilitate financing of drugs in 
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This chapter presented the major findings as specified in the objectives of the 
study, describing the different drug financing mechanisms in Uganda with an 
account of how they function. Uganda follows a pluralistic approach towards 
financing of drugs similar to that of health care financing in general. Sources of 
drug funds were identified and the flow of these funds to the various levels of 
health care providers was given. 
The study findings revealed that households serve as the largest source of drug 
funding followed by the central government including budget support from 
donors. Global initiatives in the health sector seem to be a promising major 
source of drug funding although long-term sustainability cannot be ascertained. 
The total expenditure on drugs in the health sector increased from 125 billion 
Uganda shillings in 2001/2 to 210 billion Uganda shillings in 2003/4 (excluding 
funds from the Global Fund) demonstrating a growth rate of 23 percent per 
annum over the review period. The average expenditure on drugs is 11.4% of the 
public health expenditure and comes second to expenditure on human resource. 
The study further showed that expenditure on drugs in the private sector is higher 
than that in the public sector. Finally an assessment of the sustainability of 
available drug financial resources required to meet the National Minimum Health 
Care Package drug requirement was made. The study findings show that neither 
the financial resources within the period under review (2001 - 2004) nor the 
projected drug financing resources are able to meet the predicted drug 












CHAPTER 5: DISCUSSION OF STUDY FINDINGS 
5.1 Introduction 
This chapter discusses tile key findings of the study initially by providing key 
elements on the drug financing structure in Uganda. This is followed by an 
explanation of the observed drug expenditure trends in the health sector. Finally, 
a discussion on the sustainability of "financial resources for drugs including 
sustainability of resources required for the National Minimum Health Care 
Package drug requirement is given. The study has mainly focused on drug 
'financing and expenditure and implications for sustainability of financial 
resources. It did not detail out implications for equity and implications for 
institutional sustainability. The study is limited to a period of three financial years 
which is a constraint in determining the trend of drug financing over time. 
5.2 Drug financing in Uganda 
From the study findings presented in chapter 4, drug financing is perceived by 
the Ministry of Health as significant towards the delivery of appropriate health 
services in the country. This is envisaged in the policy documents that guide the 
sector in implementation of the Health Sector Strategic Plan. Within the same 
perspective, drug financing is part of the health care financing strategy. 
Examining the public sector, the two funding mechanisms; central government 
tax revenue including donor funding and donor project support, are a principal 
source of funding for drugs especially for the public sector. The advantage with 
the central government tax revenue including donor funding is that it is relatively 
stable in terms of viability and reliability although the amount allocated to drugs is 
affected by the amount of revenue collected from taxes and the level of 
commitment from donors to support the government. On the other hand, public 











help drugs at a relatively low cost (Bennett, Quick & Velasquez 1997). 
government cannot deny its stewardship role in provid health services to 
the whole population of Uganda. However, with limited resources available 
from public budgets, it focuses on providing health including drugs to 
that the population that cannot afford; is of charge. 
In funding for drugs from central government revenue is only channeled 
through public health units, with the amount from 
it is government's responsibility to ensure equitable access to drugs, it 
is important that it encourages domestic mobilization of funds to health services 





it is seen as a vibrant sector and more efficient than the public 
drug financing mechanisms including user product 
health insurance can only benefit a of 
mechanisms depend on an individual's ability to 
mix in financing of drugs from the public sec:tor is 
financing gap between the drug need and the 




Low employment an Of"r\nnrYI\l 
agriculture make reliance on 
is extended to the government in form 
aid. Essentially loans are supposed to fund 
Unfortunately, the country has had to finance drugs, a 
recurrent cost from such loans putting the country in a more precarious 













Health sector spending on in Uganda 
illustrated earlier in section 4.3, study findings show the major source of 
drug funding to be households followed by central government revenue 
including budget support frorn Households contribute a 
amount of funds [66.5% (2001/2); 66.4% (2002/3); 57% (2003/4)] 
total funding pool for drugs in Uganda. Households mainly in 
clinics form of out-of-pocket payments 
drug shops that offer such 
namely 
at a higher cost than otherwise would 
higher cost is attributed to profit mark up, in public health 
which is regulated in the country depends on market ........ I","O~ 
DOC:Ket payments are a regressive form financing health care including 
the burden of financing is on the sick and usually from low-
income groups. Though technically efficient, private financing for is 
therapeutically inefficient because give patients drugs a 
low cost but of questionable quality 
incomplete treatments. In addition, it 
usually are either inappropriate or 
that households need to make 
more of their household income to savings and have to 
thus affecting their 
are to acquire a 
According to the National Household 
on other items like education, 
of living and a more productive 
(2003), the proportion of health 
expenditure spent on drugs increased from 39% in 2000 to 48% in 2003 (Uganda 
of Statistics 2003b). On the other hand, the decreasing trend 
household contribution towards drug funding resources over 
r'\.:::.f·' ..... 1"l may be a result of the abolition of user public health units that 
With 
into increased utilization of public health offered free of charge 
a reduction in out-of-pocket from households. 
the government of 
that not only sufficient funds are 
a big challenge to devise 
for drugs but also are 











serves as a major financing source as well as a financing agent for drugs in the 
country. Over the three financial years considered for the study, the government 
contributed on 21 % the total funding for drugs. The increase in budget 
allocation for drugs from can be explained by the following 
Wide Approach towards health development 
funding through the Ministry of Finance and 
to an increase in budget allocation to the health 
Secondly, the Poverty Eradication Action Plan 





of the Poverty Action Fund (PAF) in 
resources for PEAP priority areas 
2004b). This budget line to the 
and is disbursed as 
Primary Health 
from the central 
Conditional Grant in form of recurrent transfers for drugs 
the National Minimum 
units. When the 
Approach towards 
declined as seen in 
to local government (districts) for implementation of 
'"''''''''"''-41''' in public and private not-for-profit 
agreed with donors to use the Sector Wide 
development, the level of donor project 
1/2 (1.2%); 2002/3 (2.8%) but the 
increase in 2003/4 of up to 1 
initiatives that serve as a 
was brought about by the new wave of global 
source of funding for drugs. 
The Private organizations contributed 9% on average towards the 
total drug funding during period. government perceives this arm 
of private 
with the principle 
to 
facilities. 
funds ..,.,.. .... ,.. .. 1"'1 
in delivery of health services. In accordance 
partnership, the government offered ..., ....... ".; ....... 
organizations to purchase drugs without stipulating 
funds may used unlike that for the public sec;wr 










The lowest source of funding for drugs in the health sector was obtained from 
employers. These mainly use private health insurance as financing agents; 
comprising only 1 % of the total funding for drugs in Uganda. Although health 
insurance seems to be a preferable mechanism for funding drug needs; the rich 
subsidizing the poor and the healthy subsidizing the sick, it is not well developed 
in Uganda. Further mobilization of members into health insurance is required to 
increase coverage and make the schemes sustainable. The reason why there 
are low recruitment levels in the country is because not many Ugandans can 
afford the premiums set out by the health insurance companies and Health 
Maintenance Organizations. The level of employment in Uganda further explains 
the question of affordability. According to the Uganda National Household Survey 
(2003), only 11 % of the employed population earns US$ 100 per month (Uganda 
Bureau of Statistics 2003a). This scenario has challenging implications for the 
introduction of Social Health Insurance that mainly depends on the size of the 
formal sector, which is estimated to be 1.2% of the population (Berman et al 
2001). On the other hand, despite the small formal sector, if the scheme is well 
implemented and managed, it would reduce the number of people accessing 
public health units so that the government is left to provide drugs for the very 
poor. Community based insurance schemes were piloted in some districts but 
have not be sustainable. The major problem associated with lack of sustainability 
was that contributions are very low and cannot meet the cost of medicines even 
with subsidies. 
Spending in the health sector and macroeconomic stability 
The total drug expenditure in the health sector increased from 125 billion Uganda 
shillings in the financial year 2001/02 to 210 billion Uganda shillings in 2003/04. 
The results reveal a growing expenditure on drugs in the health sector. In this 
regard government's expenditure on drugs increased considerably within the 
period under review. This was a result of relative increased economic growth 
together with the Ministry of Health's advocacy to increase more funding to the 














was accompanied with 
upsurge of people seeking 
the government to ensure adequate and reasonable 
services. without availability of drugs 
against encouraging the population to seek health care. 
had for more funding to avail drugs in 
to in the health services rendered. 
a 
of health 
was need for 
of quality health 
ministry of health 
health so as 
come up with a new approach towards macro economic 
permanent 
(1993) argues, policy makers may to action in 




or possibilities international borrowing are 
depleted. Uganda is numbered among the Highly Indebted Countries and 
as such come up with macroeconomic the 
current account deficit. According to the Ministry of 
Planning, all sectors will have a ceiling excess 
amount of funding will be put in the treasury. All sectors would have their 
priorities and government would willingly fund these 
nt::"~'T't::>n plan. on government spending is "-"'f"T,,,,,n 
economy of country by reducing government spending, inflation to 





and increasing the strength of the 
on drug expenditure in two ways. spending 
it would mean a reduction on drug which is vital 
of the population. Secondly, limited availability of 
will affect the cost of by making them 
unaffordable. Uganda 
(Interview data). On the other hand, if 
other areas like defense and not on 
of its drugs from 
cuts are mainly in 
reduction on 











Drug financing is linked to availability of drugs. Availability of drugs depends 
among many factors on sufficient funding sources and is a key indicator towards 
determining access to drugs by the masses. Tremendous work has been carried 
out by the World Health Organization to improve access to drugs in developing 
countries (Pecoul et al 1999). This goes back to the era when the essential drug 
concept was developed and the establishment of essential drug programs in 
various developing countries. Governments have the responsibility to ensure 
that drug-financing mechanisms are managed in such a way as to achieve equity 
of access to essential drugs (Velasquez, Madrid & Quick 1998). Access to drugs 
can only be improved if the budget for drugs in the public health sector is 
sufficient to meet all the required drug needs. The scope of the study does not 
however look into the detailed accounts of equity in access to drugs. The study 
shows that in Uganda, budget allocation for drugs in the public health sector was 
far below the target despite the increments over the three-year period. This 
situation calls for government efforts to devise means to close the financing gap. 
As discussed in section 5.3 regardless of government's effort to implement health 
reforms geared towards health development the financial gap is only decreasing 
slightly. According to World Health Organizationl World Trade Organization 
(2001), for poor countries, of which Uganda is no exception, the level of 
economic growth and income limits domestic resource mobilization and 
strategies confined to ways of mobilizing domestic resources alone would be 
misdirected. Therefore, external assistance is critical to improving access to 
essential medicines. 
In the private sector, access to drugs for the poor is undeniably very low. The 
reason being that direct purchase of drugs in this sector depends on the ability to 
pay. The poor are not able to afford the cost of drugs in the private market and 
therefore have to search for free health services in the public sector which impact 
greatly on the opportunity cost in terms of travel time and waiting time. 
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The different health insurance companies visited in the study did actually provide 
drugs to their members although some had different packages for high valued 
items like anti retrovirals. This means that basic low cost items may be available 
to members but the high valued items would depend on the individual's ability to 
meet the specified higher premium. 
5.4 Sustainability of Drug Financial Resources 
In order to achieve sustainability of financing mechanisms, the viability in terms 
of generating adequate resources and the reliability of the mechanism over a 
long term must be ensured (Newbrander, Quick & Waddington 1997). No one 
mechanism on its own can achieve this desirable status. The study reveals that 
Uganda is no exception in having different alternative forms of drug financing. 
Examination of public drug financing in Uganda reveals that the sustainability of 
the government to provide funding for drugs will highly depend on the country's 
economic growth and generation of revenue. As the GOP of the country 
increased the government's commitment towards spending on drugs also 
increased at a higher rate. Although there was a corresponding increase in 
spending on drugs nevertheless, the resources were not adequate to meet the 
target set out in all the three years under review. This implies that new sources of 
funding have to be identified and strategies developed to implement them. 
With the inadequacy of government funding, the role of donors in funding health 
services including drugs becomes significant. Donor funds come in large sums 
however their sustainability is not usually assured. The results show a 
decreasing proportion of government's dependence on donors through budget 
support to the health sector. Conversely, the emergence of new global initiatives 
brings to light a new dilemma for the government to rely heavily on their support 













sustainability of global funds is assured over the medium term (2-3 years) but is 
uncertain over the long term (Interview data). 
Domestic mobilization of funds could help to bridge the gap but may have 
unwanted effects in the long run. One such mechanism was the implementation 
of cost- sharing in public health units. Studies have shown the impact of user 
fees in public health units to be negative towards the utilization of health 
services. The results show that after the abolition of cost sharing in March 2001, 
there was increased utilization of health services and an increased demand for 
drugs in public health units. The increased need together with political interests 
prompted government to allocate more funds towards the purchase of drugs for 
public health facilities. It is a well-known fact that availability of drugs in health 
facilities builds trust in health service delivery among the population. It is 
therefore clear that user fees as a funding mechanism is only sustainable for that 
part of the population that can afford and hence cannot be relied upon by the 
government if it is to meet the needs of the whole population. 
Exploring health insurance as another alternative mechanism- of drug financing 
reveals interesting findings from Uganda. The health insurance industry in 
Uganda is rather small but growing thoUgh at a very slow rate. Only 0.1 % of the 
population subscribe to private health insurance meaning that there is insufficient 
numbers to maintain sustainability. Apart from the high premiums set by the firms 
there is a lack of awareness of health insurance by the public, which explains the 
low subscriptions. In addition the quality of services offered by health insurance 
companies is no better than that offered in urban public health facilities making 
people opt for the latter. Further to this there is inadequate regulation of health 
insurance schemes and lack of organization of the health insurance sector. As 












proportion of total drug financing comes from 
by This can only be sustained by households that can to pay 
for The poor are left deprived of their household 
are worst hit by ill health. The question is how to 
in a manner that allows sharing of resources. 
is establishment of community drug financing 
to sustainable financing of drugs. These include user 
type drug revolving funds, and The 
for the success of such schemes community 
ability to pay, strong membership base, adequate administrative 
and support from the government or donors. Although, community 
have been established in with little 
drug financing scheme supported by government 
may assure continuity of financing for drugs. 





that the level of funding identified within the 
the target set out in the National Minimum 
review period (2001- 2004) and even for 
the gap is only growing bigger and is 
Given this large financing gap there is 
improving the available financing mechanisms and also 
financing the package. 






''''' .... ,'''' ... 1''''' in efficiency of delivery systems can a significant 
utilization of resources availatlle for drugs. The delivery 
health sector from a push to pull system certainly produced 
of drug funds by mainly avoiding wastages but new 












from parallel project funding to budget support through Wide 
are several streams of flow of drug funding in 
planning and implementation of drug management difficult 
flowing through credit lines have shown better efficient utilization than 
through recurrent transfers(lnterview data). It is noted individual 
parallel projects may procure drugs that are not a priority for the population 
drugs soon expire rendering them and thus 
resources. Another challenge is the introduction new ov,,,,o!"\C' 
to endemic diseases like malaria. These products once ad(jed 
requirement in the NMHCP will push the drug 















CHAPTER 6: CONCLUSION AND POLICY RECOMMENDATIONS 
6.1 Introduction 
The study gave an overview of the drug-financing situation in Uganda. The 
findings showed that not one single mechanism is sufficient to meet the drug 
needs in the country. Further to this that even with a combination of several 
mechanisms, the target drug need cannot be achieved so far. This section gives 
the main conclusions from the study and points out a number of policy 
recommendations to improve drug financing in Uganda. 
6.2 Main study conclusions 
The study revealed that financing of drugs in Uganda comes from both public 
and private sources. Different drug financing mechanisms serve different groups 
of people. Central government tax revenue is a significant source of financing 
which has been strengthened through the Sector Wide Approach to fund the 
health needs of the population more especially in the public sector. The study 
showed that donor funding in the health sector has steered increasing 
commitment of government to devote more financial resources to the health 
sector and subsequently for drugs. 
From the study findings it is clearly evident that the largest source of drug funding 
is from out-of-pocket expenditure from households. There is relatively a large 
source of financial resources for drugs in the private sector that need to be 
mobilized in such a way that people are protected from paying for drugs at the 
point of service thus avoiding impoverishment of households. 
The results show that health insurance forms a very small proportion towards the 
total drug funding pool in the country. The health insurance industry in Uganda is 











through public provision more importantly due to the high 
premiums set by the Government tax revenue is a better drug 
financing mechanism provided an appropriate tax drug 
distribution system is study shows the total drug funding to have 
increased period but is not yet 
the total drug needs 
The study also showed public drug funding was not 
drug requirement within the National Minimum Health Care Package within 
review period (2001 - 2004). Projection of the financial resources showed 
that the predicted targets for financing drugs in the minimum package would 
be achieved within the next seven 
6.3 Policy Recommendations 
The study has a 
Ugandan health 
I.;:).;:)I~C;';:) regarding financing of drugs in 
following below are suggestions for policy 
..... ol'l'or financing climate so that drugs are more 
rationally lead to a healthy and productive 
~s~)~s objective 4 in section 1.9. 
consideration so as to I"'ro",,1'o 
available to the masses and if 
population. This section 
1. Although the previous years (2001 - 2004) under study shown 
increasing government allocation to drugs, the amount expended 
sufficient to meet the quantified need. To ensure financial "' ..... ,;n.' .. it 
will necessitate government's commitment to devote 




funding in the public sector need to 
to avoid duplication of efforts and 











government including .,r\lnr\r 
of care through one efficient system 
of routine quantification of drug needs at national level should 
to determine the changing drug requirements over An 
appropriate drug procurement plan should be put in more 
use of the available drug funds in order to obtain maximum 
output. 
In of reforms within the country like fiscal decentralization 
drug funds should be protected so that it remains a key priority within 
all levels of health care delivery. 
the fact that government cannot provide all 
the population, the role of public-private partnerships is 
build upon the strength of the private sector. The 
in the drug distribution system but incentives have to 
supply of drugs to rural areas where to 
low. 
mobilization of domestic resources in the private sector to the 
more and established public health system would enable better 
funding for drugs and improved drug access. Alternatively, the 
private should organized to offer health insurance 
including drug benefits. Such arrangement would reduce out-of-










6.4 Agenda for future rA!c::A::IIlr~h 
This study has examined and 
implications for sustainability 
implications for equity on 
of access to drugs by 
Future research into pricing of drugs is 
financing, expenditure and 
is need to examine 
investigating the level 
crucial especially in the 
private sector where drugs serves as a towards access and 
rational use of drugs. There is a need to the hidden costs of drugs 
in the supply chain and determine which intervene and reduce the 
costs of drugs to patient. 
Further exploration of the role of health insurance in improving access to 
drugs including provider payment would investigation of 
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APPENDIX 1: DATA CAPTURE SHEETS 
1. Drug expenditure in the public sector 
2001/02 
Sources 
Governrnent expenditure on health 
Total expenditure on health 
Total public druuQ expenditure 
Total private drug expenditure 
External sources of funding for drugs 
2. Funds flow for drugs in the public sector 
Source Government 
Financing agent Ministry of Health 
2002/03 2003/04 
Donor support 
Ministry of Health Vertical Programs 




3. Sources and uses of funds for drugs in Private Health Insurance Companies 
Sources Uses 
Membership Government Donors Private Total Health Drugs 
































FINANCING INTERVIEW GUIDE -
(Ministry of Health, Ministry of Finance and Economic 
Form 
NB: information provided will be treated with strict confidentiality 
PARTICULARS: 
Name 
Position of rgc~nl"\nn,QnT -----------------------------------
E-mail: -------------------------------------
SECTION DRUG FINANCING POLICY 
1. Is a policy on financing health care in Uganda? 
How policy cover aspects regarding drug financing? 
How do you ensure linkage between health care 
financing policy? 
4. Do you a separate policy on drug financing? What 
Who for monitoring, evaluation and 
drug financing policy in Uganda? 
6. What are objectives of the Drug financing Pollcy? they being 




a major development within the current health 
key sources of financing 












11. Does Mid Term Expenditure Framework include d financing 
performance ind What are they? 
1 budgeted for? 
13. Have sector program priorities that could on 
for d rugs in budget allocation 
14.Are any planned health reforms underway in how are 
within national or financing partner budgets would important 
implications for drug 





health system that are likely to have a positive 
financing? 
macroeconomic issues facing the country that are ex[)ectea 
the future of drug financing? 
budget consistent with the allocated budget to a 
18.Are there any pending changes in the range of development 
are likely to participation? 
19.1s there an annual review of drug funding and 
the planning, budgeting and resource mobilization 
within the 
20. a formal developed and endorsed by the Ministry 
an in the government's share of funding for 
drug budget adequate for meeting the National Minimum 
Health drug requirement? 
22.lf not, what are for increasing drug funding? 
















SECTION B: GENERAL 
24.Are new sources and 
considered for future funding of 
25. What plans do you for 
country/organization? 
of 
26. What actions could be taken to improve 
Uganda? 
funding being 
of drug financing in the 
drug-financing situation in 
27. Do you have any other comment on financing of in Uganda? 












APPENDIX 3: DRUG FINANCING INTERVIEW GUIDE - Donor 
Form 
information provided will with strict confidentiality 
PAR1"ICULARS: 
Name of Organization: _________________ _ 
Name of respondent: _________________ _ 
Position of respondent: ________________ _ 
of interview: _________________ _ 
Location: ____________________ _ 
DRUG FINANCING 
1. What does the policy within your organization on financing health care in 
Uganda entail? 
2. How does the policy cover .... u~''"''''' regarding drug financing? 
How have the impact of donor Qt1' ... ,rt~ been realized as 
drugs is concemed in the (2001 - 2004)? 
4. What are the main nOB::>r."., 
5. there any conditionality for 
sector? 
6. What are the potential health 
on funding for drugs? 
for in the health sector? 
or loans extended to the health 











financing a major development 
for your organization? 
within the current funding 
8. give a brief description of the resource allocation process? 
9. there any planned changes in strategy of financing 
a. Are these likely to a impact on drug financing? 
GENERAL 
10. new sources and mechanisms of internal and external funding 
considered for future funding of drugs? 
11. What plans do you have for sustainability 
organization? 
drug funding your 
1 What could be taken to improve the drug-financing situation in 
1 any other comment on financing of drugs in Uganda? 











APPENDIX 4: PRIVATE INSURANCE INTERVIEW GUIDE 
Form No: ----
NB: The information provided will be treated with strict confidentiality 
Name of Firm: -----------------------
Name of Respondent: _________________ _ 
Position of respondent: ___________________ _ 
Date of interview: -----------------
Location: --------------------------
E- mail: -------------------------
Type of Firm (circle one) 
1 ::: State-Owned! Parastatal 2 ::: Private - for - profit 
1. Please provide a brief description of your firm's activities 
2. How many members are covered by your organization? 
3. Who funds the health insurance scheme? 
4. How are contributions collected? 
5. Does the government or any other organization make a contribution to 
health care benefits provided by your firm? 
6. What kind of membership do you have? Group or Company! Individual! 
Individual + Family 












8. Which types of health care services are covered? 
9. What exclusions do you have? 
10. Which providers are paid for the health services? 
Government of Uganda Hospitals 
Private for profit Hospitals 
Not for Profit 
Reimbursement made directly to premium holder 
11. How much was spent/reimbursed on health services in 2001/2 
to 2003/4? 
12. How much was spent/reimbursed on drugs in the years 2001/2 2003/4? 
13. Do you have any other I"'nrnrn.:::on'l' on drug and 














APPENDIX AUTHORIZATION TO ACCESS RECORDS 






RE: RESEARCH ON FINANCING MECHANISMS IN UGANDA 
This is to introduce to you Kate Kikule, a postgraduate student currently pursuing 
a Masters in Public Health 
University of Capetown, South 
She is engaged in a study on drug 
For this purpose she no,:orlc:: your 
out interviews and access relevant ro."'l"\rrt 
Please accord her all the nec:es~)a 
The Ministry of Health has authorized 
DR. J. H. KYABAGGU 
PERMANENT 
in Health Economics) degree, at the 
mechanisms in Uganda. 













APPENDIX 6: INFORMED CONSENT FORM 
The study for which your participation is requested 






This study your 
any way have personal 
are for research purposes only and will not in 
or any liability. 
You will be 
interview. 
to to some questions during a 
Your answers to the q and other information provided by you will only 
used for purpose of the and your name will be used for 
purposes only. You are that your identity and the information will 
be treated with strict confidentiality. 
You have the right to 
in time. 
I have read and 
part in this study as a 
any time without 
Date: -----------------------------------
or withdraw study point 
~n/"l\J'::' information. I consent voluntarily to 
and have the right to withdraw form the at 
to my work or me. 
S ig natu re: ------------------------------
Name of Researcher: ------------------------------------------
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